# Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma

> **NCT05525286** · PHASE1,PHASE2 · TERMINATED · sponsor: **SOTIO Biotech a.s.** · enrollment: 31 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** SOT102

## Key facts

- **NCT ID:** NCT05525286
- **Lead sponsor:** SOTIO Biotech a.s.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-31
- **Primary completion:** 2024-12-13
- **Final completion:** 2024-12-13
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Trial terminated by Sponsor based on benefit- risk reassessment
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525286, "Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05525286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*